1067. Differential Gene Expression Elicited by Children in Response to the 2015-16 Live Attenuated versus Inactivated Influenza Vaccine
Session: Poster Abstract Session: Assorted Pediatric Vaccines
Friday, October 6, 2017
Room: Poster Hall CD
Posters
  • IDWeek poster Oct 2017.pdf (238.4 kB)
  • Differential Gene Expression Elicited by Children in Response to the 2015-16 Live Attenuated versus Inactivated Influenza Vaccine

    Kelly Stefano Cole, PhD, 1 Judith M. Martin, MD, 2 William T. Horne, II, MS,2 Chyongchiou J. Lin, PhD, 3 Mary Patricia Nowalk, PhD, RD, 3 Richard K. Zimmerman, MD, MPH, MA3

     

    Background: In recent influenza seasons, the live attenuated influenza vaccine (LAIV) has not demonstrated the same level of vaccine effectiveness as that observed among children who received the inactivated influenza vaccine (IIV).  To better understand this difference, this study compared the mRNA sequencing transcription profile (RNA seq) in children who received either IIV or LAIV.

    Methods: Children 3-17 years of age receiving quadrivalent influenza vaccine were enrolled.  Blood samples were collected on Day 0 prior to vaccination and again on Day 7 (range 6-10 days) following vaccination.  Total RNA was isolated from PAXgene tubes and sequenced for a custom panel of 89 transcripts using the TruSeq Targeted RNA Expression method.  Fold differences in normalized RNA seq counts from Day 0 to Day 7 were calculated, log2 transformed and compared between the two vaccine groups.

    Results:  Of 73 children, 47 received IIV and 26 received LAIV.  Following IIV vaccination, 12 genes demonstrated significant differential expression at Day 7.  In contrast, following LAIV vaccination, seven genes demonstrated significant differential expression at Day 7, five of which were not differentially expressed by IIV.  Two genes demonstrated similar patterns of regulation in both IIV and LAIV recipients. 

    Conclusion:  Differential regulation of genes was observed between 2015-16 LAIV and IIV recipients.  These results help to elucidate the immune response to influenza vaccines and might help explain the difference in vaccine effectiveness observed in recent years between LAIV and IIV.

     

    Richard Zimmerman, MD, MPH, FIDSA1, Kelly Cole, PhD2, Judith Martin, MD3, William Horne II, MS4, Chyongchiou J Lin, PhD1 and Mary Patricia Nowalk, PhD RD1, (1)Family Medicine, University of Pittsburgh, Pittsburgh, PA, (2)University of Pittsburgh, Pittsburgh, PA, (3)Children's Hospital of Pittsburgh, Pittsburgh, PA, (4)Pediatrics, Children's Hospital of Pittsburgh, Pittsburgh, PA

    Disclosures:

    R. Zimmerman, Sanofi Pasteur: Grant Investigator , Research grant
    Merck & Co, Inc: Grant Investigator , Research grant
    Pfizer, Inc: Grant Investigator , Research grant

    K. Cole, None

    J. Martin, None

    W. Horne II, None

    C. J. Lin, Sanofi: Grant Investigator , Research grant
    Merck & Co, Inc: Grant Investigator , Research grant
    Pfizer, Inc.: Grant Investigator , Research grant

    M. P. Nowalk, Merck & Co, Inc: Grant Investigator , Research grant
    Pfizer, Inc.: Grant Investigator , Research grant

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.